{
  "abstract": "The fast evolution of mRNA-based cancer therapeutics requires advanced frameworks to overcome the challenges of tumor heterogeneity and the immunosuppressive tumor immune microenvironment. In this context, single-cell technologies enable characterization of immune cell subsets, intercellular communication, and therapy resistance drivers. The shift to single-cell profiling provides a transition toward the development of precision mRNA treatments tailored to the unique dynamics of an individual tumor.",
  "abstract_shown": true,
  "affiliations": [
    "Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia",
    "Research Institute of Molecular and Cellular Medicine, Peoples’ Friendship University of Russia (RUDN University), Moscow, Russia"
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Ekaterina V. Ovcharenko"
    },
    {
      "affs": [
        0
      ],
      "name": "Marina R. Patysheva"
    },
    {
      "affs": [
        0
      ],
      "name": "Kirill M. Kirilenko"
    },
    {
      "affs": [
        0
      ],
      "name": "Arina A. Ibragimova"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Evgeny V. Denisov"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/4kz2fdeah4dea.bib",
  "cited_by": 0,
  "doi": "10.1038/s41541-026-01529-2",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13748535/",
  "id": "4kz2fdeah4dea",
  "issns": [
    "2059-0105"
  ],
  "landing_url": "https://doi.org/10.1038/s41541-026-01529-2",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Perspective"
    ],
    [
      "openalex",
      "2730|Cancer Immunotherapy and Biomarkers"
    ]
  ],
  "openalex": "W7169670846",
  "pdf_url": "https://www.nature.com/articles/s41541-026-01529-2_reference.pdf",
  "pmcid": "PMC13748535",
  "pmid": "42471337",
  "published": "2026-07-18",
  "publisher": "Nature Publishing Group",
  "ris": "https://research.draconitic.com/paper/4kz2fdeah4dea.ris",
  "sources": [
    {
      "first_seen": "2026-11-13T12:26:31Z",
      "native_id": "PMC13748535",
      "source": "pmc",
      "url": "https://doi.org/10.1038/s41541-026-01529-2"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Cancer Immunotherapy and Biomarkers",
      "subfield": "oncology"
    }
  ],
  "title": "Single-cell technologies in mRNA cancer vaccines",
  "title_text": "Single-cell technologies in mRNA cancer vaccines",
  "type": "peer-reviewed",
  "updated_at": "2026-11-13T12:26:31Z",
  "url": "https://research.draconitic.com/paper/4kz2fdeah4dea",
  "venue": "NPJ Vaccines",
  "versions": []
}